SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being... It is being developed as an adjunct to chemotherapy.
- Mechanism
- Curator reviewed
SPI-1620 is a highly selective peptide agonist of endothelin-B receptors, which can stimulate receptors on endothelial cells, the innermost layer of cells lining the blood vessels. The blood supply to tumors is different than the blood supply to healthy organs. Blood vessels in the growing part of tumors are relatively devoid of smooth muscle covering and are rich in endothelial cells. Therefore, by stimulating the endothelial-B receptors present on the endothelial cells, SPI-1620 should selectively increase tumor blood flow while sparing healthy tissue.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
- Code names
- IRL-1620 · PMZ-1620 · SPI-1620
Resolves to
What you can answer from here — as of September 24, 2025
Which drugs share a target with Sovateltide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account